Advertisement
Advertisement
BMRN
BioMarin Pharmaceuticals Inc
60.26
USDSponsored
-1.09
-1.78%
Sep 25, 15:59 UTC -4
Closed
After-Market
59.80
-0.46
-0.77%
BMRN Earnings Reports
Positive Surprise Ratio
BMRN beat 30 of 43 last estimates.
70%
Next Report
Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.05B
/$0.75
Implied change from Q2 26 (Revenue/ EPS)
+6.01%
/+2.74%
Implied change from Q3 25 (Revenue/ EPS)
+35.18%
/-568.75%
BioMarin Pharmaceuticals Inc earnings per share and revenue
On Aug 06, 2026, BMRN reported earnings of 0.73 USD per share (EPS) for Q2 26, beating the estimate of 0.70 USD, resulting in a 4.05% surprise. Revenue reached 989.71 million, compared to an expected 945.45 million, with a 4.68% difference. The market reacted with a +3.82% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of 0.75 USD, with revenue projected to reach 1.05 billion USD, implying an increase of 2.74% EPS, and increase of 6.01% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were BioMarin Pharmaceuticals Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, BioMarin Pharmaceuticals Inc reported EPS of $0.73, beating estimates by 4.05%, and revenue of $989.71M, 4.68% above expectations.
How did the market react to BioMarin Pharmaceuticals Inc's Q2 2026 earnings?
The stock price moved up 3.82%, changed from $61.46 before the earnings release to $63.81 the day after.
When is BioMarin Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Oct 26, 2026.
What are the forecasts for BioMarin Pharmaceuticals Inc's next earnings report?
Based on --
analysts, BioMarin Pharmaceuticals Inc is expected to report EPS of $0.75 and revenue of $1.05B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.